The safety of pharmacological treatment options for lupus nephritis

References

• Pons-Estel BA, Catoggio LJ, Cardiel MH, et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among “Hispanics”. Medicine (Baltimore). 2004 Jan;83(1):1–17.
   PubMed Web of Science ®Google Scholar
• Hanly JG, O’Keeffe AG, Su L, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford). 2016 Feb;55(2):252–262.
   PubMed Web of Science ®Google Scholar
• Chan TM. Treatment of severe lupus nephritis: the new horizon. Nat Rev Nephrol. 2015 Jan;11(1):46–61.
   PubMed Web of Science ®Google Scholar
• Muehrcke RC, Kark RM, Pirani CL, et al. Histological and clinical evolution of lupus nephritis. Ann Rheum Dis. 1955 Dec;14(4):371–377.
   PubMed Web of Science ®Google Scholar
• Weening JJ, D’Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004 Feb;15(2):241–250.
   PubMed Web of Science ®Google Scholar
• Hui M, Garner R, Rees F, et al. Lupus nephritis: a 15-year multi-centre experience in the UK. Lupus. 2013 Mar;22(3):328–332.
   PubMed Web of Science ®Google Scholar
• Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 2013 Aug;65(8):2154–2160.
   PubMed Web of Science ®Google Scholar
• Mok CC. Towards new avenues in the management of lupus glomerulonephritis. Nat Rev Rheumatol. 2016 Jan;12:221–234.
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Danza A, Perales I, et al. Prednisone in lupus nephritis: how much is enough? Autoimmun Rev. 2014 Feb;13(2):206–214.
   PubMed Web of Science ®Google Scholar
• Grootscholten C, Ligtenberg G, Hagen EC, et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int. 2006 Aug;70(4):732–742.
   PubMed Web of Science ®Google Scholar
• Moroni G, Gallelli B, Quaglini S, et al. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol Dial Transplant. 2006 Jun;21(6):1541–1548.
   PubMed Web of Science ®Google Scholar
• Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011 Nov;365(20):1886–1895.
   PubMed Web of Science ®Google Scholar
• Houssiau FA, D’Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN nephritis trial. Ann Rheum Dis. 2010;69(12):2083–2089.
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Vasconcelos C, D’Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the euro-lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46(8):2121–2131.
   PubMed Web of Science ®Google Scholar
• Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004 Mar;350(10):971–980.
   PubMed Web of Science ®Google Scholar
• Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010;62(1):9–21.
   PubMed Web of Science ®Google Scholar
• Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou nephrology study group. N Engl J Med. 2000 Oct;343(16):1156–1162.
   PubMed Web of Science ®Google Scholar
• Chan TM, Tse KC, Tang CS, et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005 Apr;16(4):1076–1084.
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005 Nov;353(21):2219–2228.
   PubMed Web of Science ®Google Scholar
• Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009 May;20(5):1103–1112.
   PubMed Web of Science ®Google Scholar
• Austin HA, Illei GG, Braun MJ, et al. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol. 2009 Apr;20(4):901–911.
   PubMed Web of Science ®Google Scholar
• Chen W, Tang X, Liu Q, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis. 2011 Feb;57(2):235–244.
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhang H, Xing C, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015 Jan;162(1):18–26.
   PubMed Web of Science ®Google Scholar
• Mok CC, Ying KY, Yim CW, et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann Rheum Dis. 2016 Jan;75(1):30–36.
   PubMed Web of Science ®Google Scholar
• Bao H, Liu ZH, Xie HL, et al. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008 Oct;19(10):2001–2010.
   PubMed Web of Science ®Google Scholar
• Austin HA, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986 Mar;314(10):614–619.
   PubMed Web of Science ®Google Scholar
• Gourley MF, Austin HA, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996 Oct;125(7):549–557.
   PubMed Web of Science ®Google Scholar
• Eckardt KU, Kasiske BL. Kidney disease: improving global outcomes. Nat Rev Nephrol. 2009 Nov;5(11):650–657.
   PubMed Web of Science ®Google Scholar
• Zeher M, Doria A, Lan J, et al. Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus. 2011 Dec;20(14):1484–1493.
   PubMed Web of Science ®Google Scholar
• Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013 Aug;72(8):1280–1286.
   PubMed Web of Science ®Google Scholar
• Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009 Jul;68(7):1119–1124.
   PubMed Web of Science ®Google Scholar
• Sabio JM, Vargas-Hitos JA, Navarrete N, et al. Effects of low or medium-dose of prednisone on insulin resistance in patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2010 Jul–Aug;28(4):483–489.
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, et al. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther. 2009;11(4):R109.
   PubMed Web of Science ®Google Scholar
• Petri M, Spence D, Bone LR, et al. Coronary artery disease risk factors in the Johns Hopkins lupus cohort: prevalence, recognition by patients, and preventive practices. Medicine (Baltimore). 1992 Sep;71(5):291–302.
   PubMed Web of Science ®Google Scholar
• Bultink IE, Harvey NC, Lalmohamed A, et al. Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom. Osteoporos Int. 2014 Apr;25(4):1275–1283.
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003 Nov;48(11):3224–3229.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004 Jun;19(6):893–899.
   PubMed Web of Science ®Google Scholar
• Monster TB, Janssen WM, de Jong PE, et al. Corticosteroid use and its association with microalbuminuria in the adult population. Pulm Pharmacol Ther. 2003;16(6):349–353.
   PubMed Web of Science ®Google Scholar
• Elion GB. The George Hitchings and Gertrude Elion lecture. The pharmacology of azathioprine. Ann N Y Acad Sci. 1993 Jun;685:400–407.
   PubMed Web of Science ®Google Scholar
• Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med. 1984 Dec;311(24):1528–1533.
   PubMed Web of Science ®Google Scholar
• Henderson LK, Masson P, Craig JC, et al. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2013 Jan;61(1):74–87.
   PubMed Web of Science ®Google Scholar
• Chen W, Liu Q, Tang X, et al. Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial. Lupus. 2012 Aug;21(9):944–952.
   PubMed Web of Science ®Google Scholar
• Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum. 1991 Aug;34(8):945–950.
   PubMed Web of Science ®Google Scholar
• Donadio JV, Holley KE, Ferguson RH, et al. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med. 1978 Nov;299(21):1151–1155.
   PubMed Web of Science ®Google Scholar
• Steinberg AD, Decker JL. A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis. Arthritis Rheum. 1974 Nov–Dec;17(6):923–937.
   PubMed Web of Science ®Google Scholar
• Boumpas DT, Austin HA, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992 Sep;340(8822):741–745.
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Vasconcelos C, D’Cruz D, et al. The 10-year follow-up data of the euro-lupus nephritis trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010 Jan;69(1):61–64.
   PubMed Web of Science ®Google Scholar
• Bose B, Silverman ED, Bargman JM. Ten common mistakes in the management of lupus nephritis. Am J Kidney Dis. 2014 Apr;63(4):667–676.
   PubMed Web of Science ®Google Scholar
• Wofsy D, Diamond B, Houssiau FA. Crossing the Atlantic: the euro-lupus nephritis regimen in North America. Arthritis Rheumatol. 2015 May;67(5):1144–1146.
   PubMed Web of Science ®Google Scholar
• Houssiau FA. Moving East: the euro-lupus nephritis regimen in Asia. Kidney Int. 2016 Jan;89(1):25–27.
   PubMed Web of Science ®Google Scholar
• Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012 Jun;64(6):797–808.
   PubMed Web of Science ®Google Scholar
• Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012 Nov;71(11):1771–1782.
   PubMed Web of Science ®Google Scholar
• Mok CC, Ying KY, Ng WL, et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med. 2006 Apr;119(4):355.e25–33.
   PubMed Web of Science ®Google Scholar
• Somers EC, Marder W, Christman GM, et al. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum. 2005;52(9):2761–2767.
   PubMed Web of Science ®Google Scholar
• Arends S, Grootscholten C, Derksen RH, et al. Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis. Ann Rheum Dis. 2012 Jun;71(6):966–973.
   PubMed Web of Science ®Google Scholar
• Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000 May;47(2–3):85–118.
   PubMed Web of Science ®Google Scholar
• Ong LM, Hooi LS, Lim TO, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton). 2005 Oct;10(5):504–510.
   PubMed Web of Science ®Google Scholar
• Touma Z, Gladman DD, Urowitz MB, et al. Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol. 2011 Jan;38(1):69–78.
   PubMed Web of Science ®Google Scholar
• Kuiper-Geertsma DG, Derksen RH. Newer drugs for the treatment of lupus nephritis. Drugs. 2003;63(2):167–180.
   PubMed Web of Science ®Google Scholar
• Isenberg D, Appel GB, Contreras G, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford). 2010;49(1):128–140.
   PubMed Web of Science ®Google Scholar
• Lee YH, Woo JH, Choi SJ, et al. Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis. Lupus. 2010 May;19(6):703–710.
   PubMed Web of Science ®Google Scholar
• Zhu B, Chen N, Lin Y, et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant. 2007 Jul;22(7):1933–1942.
   PubMed Web of Science ®Google Scholar
• Tamirou F, D’Cruz D, Sangle S, et al. Long-term follow-up of the MAINTAIN nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis. 2016;75(3):526–531.
   PubMed Web of Science ®Google Scholar
• Contreras G, Tozman E, Nahar N, et al. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus. 2005;14(Suppl 1):s33–s38.
   PubMed Web of Science ®Google Scholar
• Flint J, Panchal S, Hurrell A, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford). 2016. pii: kev404. Epub 2016 Jan 10.
   Google Scholar
• Chou HH, Chen MJ, Chiou YY. Enteric-coated mycophenolate sodium in pediatric lupus nephritis: a retrospective cohort study. Clin Exp Nephrol. 2015 Oct. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Traitanon O, Avihingsanon Y, Kittikovit V, et al. Efficacy of enteric-coated mycophenolate sodium in patients with resistant-type lupus nephritis: a prospective study. Lupus. 2008 Aug;17(8):744–751.
   PubMed Web of Science ®Google Scholar
• Heidt S, Roelen DL, Eijsink C, et al. Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. Clin Exp Immunol. 2010 Feb;159(2):199–207.
   PubMed Web of Science ®Google Scholar
• Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008 Sep;14(9):931–938.
   PubMed Web of Science ®Google Scholar
• Zavada J, Pesickova S, Rysava R, et al. Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus. 2010 Oct;19(11):1281–1289.
   PubMed Web of Science ®Google Scholar
• Hallegua D, Wallace DJ, Metzger AL, et al. Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature. Lupus. 2000;9(4):241–251.
   PubMed Web of Science ®Google Scholar
• Tam LS, Li EK, Leung CB, et al. Long-term treatment of lupus nephritis with cyclosporin A. QJM. 1998 Aug;91(8):573–580.
   PubMed Web of Science ®Google Scholar
• Dostál C, Tesar V, Rychlík I, et al. Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. Lupus. 1998;7(1):29–36.
   PubMed Web of Science ®Google Scholar
• Webster P, Wardle A, Bramham K, et al. Tacrolimus is an effective treatment for lupus nephritis in pregnancy. Lupus. 2014 Oct;23(11):1192–1196.
   PubMed Web of Science ®Google Scholar
• Pisoni CN, D’Cruz DP. The safety of mycophenolate mofetil in pregnancy. Expert Opin Drug Saf. 2008 May;7(3):219–222.
   PubMed Web of Science ®Google Scholar
• Croca SC, Rodrigues T, Isenberg DA. Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology (Oxford). 2011 Aug;50(8):1424–1430.
   PubMed Web of Science ®Google Scholar
• Houssiau FA. Biologic therapy in lupus nephritis. Nephron Clin Pract. 2014;128(3–4):255–260.
   PubMedGoogle Scholar
• Dolff S, Berden JH, Bijl M. Treatment of lupus nephritis. Expert Rev Clin Immunol. 2010;6(6):901–911.
   PubMed Web of Science ®Google Scholar
• Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012;64(4):1215–1226.
   PubMed Web of Science ®Google Scholar
• Mysler EF, Spindler AJ, Guzman R, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum. 2013 Sep;65(9):2368–2379.
   PubMed Web of Science ®Google Scholar
• Furie R, Nicholls K, Cheng TT, et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol. 2014;66(2):379–389.
   PubMed Web of Science ®Google Scholar
• ACCESS TG. Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study. Arthritis Rheumatol. Nov 2014;66(11):3096–3104.
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Wax S, Rajeswaran A, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther. 2012;14(1):R33.
   PubMed Web of Science ®Google Scholar
• Thornton CC, Ambrose N, Ioannou Y. Ofatumumab: a novel treatment for severe systemic lupus erythematosus. Rheumatology (Oxford). 2015 Mar;54(3):559–560.
   PubMed Web of Science ®Google Scholar
• Isenberg DA, Petri M, Kalunian K, et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Feb;75(2):323–331.
   PubMed Web of Science ®Google Scholar
• Furie RA, Leon G, Thomas M, et al. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis. 2015 Sep;74(9):1667–1675.
   PubMed Web of Science ®Google Scholar
• Petri M, Wallace DJ, Spindler A, et al. Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum. 2013 Apr;65(4):1011–1021.
   PubMed Web of Science ®Google Scholar
• Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010 Feb;62(2):542–552.
   PubMed Web of Science ®Google Scholar
• Barilla-Labarca ML, Toder K, Furie R. Targeting the complement system in systemic lupus erythematosus and other diseases. Clin Immunol. 2013 Sep;148(3):313–321.
   PubMed Web of Science ®Google Scholar
• Jayne D, Appel G, Chan TM, et al. LB0003 A randomized controlled study of laquinimod in active lupus nephritis patients in combination with standard of care. Ann Rheum Dis. 2013 June 1;72(Suppl3):A164.
   Google Scholar
• Cardiel MH, Tumlin JA, Furie RA, et al. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum. 2008 Aug;58(8):2470–2480.
   PubMed Web of Science ®Google Scholar
• Alexander T, Sarfert R, Klotsche J, et al. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis. 2015 Jul;74(7):1474–1478.
   PubMed Web of Science ®Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010 Jan;62(1):222–233.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012 Aug;71(8):1343–1349.
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011 Feb;377(9767):721–731.
   PubMed Web of Science ®Google Scholar
• Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. June 2012;5:2013.
   Google Scholar
• de la Torre I, Leandro MJ, Edwards JC, et al. Baseline serum immunoglobulin levels in patients with rheumatoid arthritis: relationships with clinical parameters and with B-cell dynamics following rituximab. Clin Exp Rheumatol. 2012 Jul–Aug;30(4):554–560.
   PubMed Web of Science ®Google Scholar
• Heusele M, Clerson P, Guery B, et al. Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab. Clin Rheumatol. 2014 Jun;33(6):799–805.
   PubMed Web of Science ®Google Scholar
• Henegar CE, Eudy AM, Kharat V, et al. Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review. Lupus. 2016;25:617–626.
   PubMed Web of Science ®Google Scholar
• Isenberg D, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015;74(11):2006–2015.
   PubMed Web of Science ®Google Scholar
• Cogollo E, Silva MA, Isenberg D. Profile of atacicept and its potential in the treatment of systemic lupus erythematosus. Drug Des Devel Ther. Mar 2015;5(9):1331–1339. doi:10.2147/DDDT.S71276.
   Web of Science ®Google Scholar
• Hoi AY, Littlejohn GO. Abatacept in the treatment of lupus. Expert Opin Biol Ther. 2012 Oct;12(10):1399–1406.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven R, Aranow C, Rovin B, et al. OP0047Abstract A phase 2, multicenter, randomized, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy and safety of sirukumab in patients with active lupus nephritis. Ann Rheum Dis. 2014 June 1;73(Suppl2):78.
   Web of Science ®Google Scholar
• Xu Z, Bouman-Thio E, Comisar C, et al. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol. 2011 Aug;72(2):270–281.
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Navarra S, Petri MA, et al. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus. 2013 Feb;22(2):144–154.
   PubMed Web of Science ®Google Scholar
• Horowitz DM, Furie RA. Abetimus sodium: a medication for the prevention of lupus nephritis flares. Expert Opin Pharmacother. 2009 Jun;10(9):1501–1507.
   PubMed Web of Science ®Google Scholar